Molina KC, Ginde AA. Real-world use of nirmatrelvir–ritonavir: who benefits? Lancet Infect Dis 2023; published online March 15. https://doi.org/10.1016/S1473-3099(23)00180-9—In this Comment, Adit A Ginde's affiliation should have been “Department of Emergency Medicine, Colorado University School of Medicine, Aurora, CO, USA”. This correction has been made to the online version as of March 29, 2023, and will be made to the printed version.
. 2023 Mar 29;23(5):e166. doi: 10.1016/S1473-3099(23)00196-2
Correction to Lancet Infect Dis 2023; published online March 15. https://doi.org/10.1016/S1473-3099(23)00180-9
Issue date 2023 May.
© 2023 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC10058660 PMID: 37003291
This corrects the article "Real-world use of nirmatrelvir–ritonavir: who benefits?" on page 765.